RxDoctor Payments Data

Shelly Collins

Family · Moberly, MONPI 1508275512

Payments from drug & device makers

$8,782in general payments, 2019–2025

Across 429 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$769
  • Otsuka America Pharmaceutical, Inc.$390
  • Abbott$346
  • Johnson & Johnson$301
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$8,782100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,782 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$103,073
Medicare patients
337
Services billed
3,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide68$97,563
EliquisApixaban135$97,257
JardianceEmpagliflozin78$74,176
FarxigaDapagliflozin Propanediol89$62,282
TrulicityDulaglutide46$57,538
OzempicSemaglutide56$57,032
EntrestoSacubitril/Valsartan56$55,475
Invega SustennaPaliperidone Palmitate17$53,006
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$52,487
Breztri AerosphereBudesonide/Glycopyr/Formoterol50$34,738
XareltoRivaroxaban44$30,274
Teriparatide16$26,608
VraylarCariprazine Hcl15$21,908
Xigduo XrDapaglifloz Propaned/Metformin13$20,288
Liothyronine Sodium289$18,413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$769$155,100114 claims
AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere$1,485$107,999164 claims
PfizerEliquis$219$97,257135 claims
Johnson & JohnsonInvega Sustenna, Xarelto$301$83,28061 claims
Boehringer IngelheimJardiance, Synjardy Xr$233$82,00391 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$256$66,90495 claims
Novo NordiskOzempic$293$57,03256 claims
NovartisEntresto$253$55,47556 claims
AbbVieVraylar, Linzess, Armour Thyroid$1,599$34,98772 claims
Sanofi-aventis U.S. LLCLantus$60$1,98922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.

Other family in Moberly

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →